Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8943087 | 0.83 | NAAA (0.45) | TYRNAAAIDO1HCAR3TRPV1 | |
| SCHEMBL1789729 | 0.83 | NAAA (0.45) | TYRNAAAIDO1HCAR3TRPV1 | |
| SCHEMBL29045180 | 0.79 | TYR (0.47) | TYRNAAAIDO1HCAR3TRPV1 | |
| SCHEMBL5678097 | 0.79 | CNR1 (0.38) | NAAAIDO1HCAR3NPC1HPGD | |
| SCHEMBL5920724 | 0.78 | HCAR3 (0.42) | NAAAALOX5HCAR3 | |
| SCHEMBL1954257 | 0.76 | NAAA (0.48) | NAAAALOX5IDO1HCAR3TRPV1 | |
| SCHEMBL1952774 | 0.76 | NAAA (0.48) | NAAAALOX5IDO1HCAR3TRPV1 | |
| SCHEMBL10908922 | 0.76 | NAAA (0.46) | NAAAALOX5IDO1HTTEP300 | |
| SCHEMBL1952285 | 0.76 | NAAA (0.48) | NAAAALOX5IDO1HCAR3TRPV1 | |
| SCHEMBL1954034 | 0.76 | NAAA (0.48) | NAAAALOX5IDO1HCAR3TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | ZHAO BAIYI | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | COMT, CD69, SPR | TYR 275/4885NAAA 1064/4885ALOX5 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.